Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp (NASDAQ:WGS), sold 17,179 shares of the company's Class A Common Stock on March 16, 2026, generating roughly $1.32 million in proceeds. The disposition occurred across multiple transactions, with execution prices spanning $76.3492 to $77.9354 per share.
According to the filing, the share sales were executed to cover tax withholding obligations tied to the vesting and settlement of Restricted Stock Units - RSUs - and were not discretionary transactions by Stueland. The filing also shows that on March 15 and 16, 2026, Stueland exercised options to acquire 30,671 shares of Class A Common Stock upon settlement for no consideration.
After the reported sale, Stueland is listed as beneficially owning 58,447 shares of Class A Common Stock. She additionally holds RSUs that represent the contingent right to receive up to 414,695 shares and options to purchase as many as 107,610 shares of Class A Common Stock, all of which vest according to their respective schedules.
The company's stock is currently trading at $75.50, having fallen about 15 percent over the past week and 42 percent year-to-date. Notwithstanding the recent weakness, InvestingPro analysis cited in the filing indicates the shares may be undervalued at current levels, and analysts continue to maintain bullish price targets for the name ranging from $130 to $177. InvestingPro is also noted as providing 10 additional exclusive tips for WGS subscribers.
GeneDx reported mixed results for the fourth quarter, missing earnings expectations while slightly topping revenue forecasts. Revenue for the quarter was $121.0 million, a 27 percent increase year-over-year and above the consensus estimate of $120.4 million. Within the company, the WES/WGS segment produced $104.0 million in revenue, marking 32 percent year-over-year growth.
Competitive pressures are emerging in the diagnostic genomics market. The filing references a new offering from a peer, with Natera Inc. launching Zenith genomics - a whole genome sequencing test for rare disease diagnosis - which could influence GeneDx's market position.
Brokerage reactions to the latest developments have varied but remain mostly constructive. BTIG reduced its price target for GeneDx to $170 from $200, citing a back-end loaded growth outlook, while retaining a Buy rating. TD Cowen reiterated a Buy rating with a $165 price target. Canaccord Genuity likewise reaffirmed a Buy rating and set a $170 price target, pointing to the company's revenue performance.
These insider moves, quarterly results and competitive activity together frame the current investor debate around valuation and growth timing for GeneDx. The share sale by the CEO was administrative in nature, tied to tax obligations from RSU settlement, and was accompanied by option exercises and continued substantial potential equity exposure through outstanding RSUs and option grants.